The Ballad of TIGIT

# Summary TIGIT drugs were developed as the next generation of cancer immunotherapy following the blockbuster success of Keytruda, with the theory that blocking the TIGIT protein could release multiple immune brakes simultaneously to fight tumors more effectively. However, the article indicates that TIGIT drugs have recently become scientifically radioactive and considered untouchable by serious researchers, despite initial promise and significant pharmaceutical investment. The piece uses this story to illustrate how certain drug classes can consume billions in development before ultimately disappointing, similar to amyloid-beta treatments for Alzheimer's.